AbCellera Biologics Inc. (ABCL) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Vancouver, BC, カナダ. 現CEOは Carl Hansen.
ABCL を有する IPO日 2020-12-11, 596 名の正社員, に上場 NASDAQ Global Select, 時価総額 $1.14B.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
